SCLX_OUT_1 [2025-04-29 06:43:23 -0400] 7202 Bytes | 1941 tokens | Cum: 1941 tkns (24.26% of 8k)
==========================================================================

You're the expert here today. I just pulled together a bunch of data for you to look over real fast. I'm looking at high-performance stocks today and Scilex (SCLX) hit my radar screen, up to $5.21 from a prev close of $4.67 Do you think its got more juice or is it lacking potential? It's 6:43 AM on Tue Apr 29, 2025 and I have to decide: buy or sell!

--- COMPANY PROFILE ---
Company: Scilex (SCLX)
IPO: IPO date unknown
Shares Outstanding: 243,310,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS

Here’s a list of headlines for Scilex:

Apr-22-25 09:00AM - Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025
Apr-16-25 02:12PM - Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis
Apr-15-25 09:00AM - Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB 's Acute Treatment of Migraine With or Without Aura in Canada
Apr-12-25 09:51AM - Scilex downgraded to Hold from Buy at D. Boral Capital
Apr-11-25 09:00AM - Scilex Holding Company Announces 1-for-35 Reverse Stock Split
Mar-26-25 08:24PM - Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva
Mar-10-25 09:00AM - Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from January 28, 2025 to April 11, 2025
Jan-31-25 09:00AM - Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025
Jan-22-25 08:00AM - Scilex Holding Company Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB in Acute Pain Indication
Jan-21-25 11:49AM - Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)
Jan-21-25 11:49AM 09:46AM - Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025
Jan-21-25 11:49AM 09:00AM - Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC
Jan-21-25 11:49AM 07:00AM - Scilex Holding Company Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB in Acute Pain Indication
Jan-21-25 11:49AM 06:00AM - Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024
Jan-16-25 03:38PM - Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba , an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults
Jan-14-25 09:22AM - Scilex announces Pain Medicine News published data on ZTildo vs Lidocaine 5%
Jan-13-25 09:00AM - Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido vs. Lidocaine 5% Patch
Jan-08-25 04:00PM - Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
Dec-30-24 09:00AM - Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from November 7, 2024 to January 28, 2025
Dec-16-24 09:00AM - Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation
Dec-13-24 12:23PM - Scilex Holding Company Announces Closing of $17 Million Registered Direct Offering
Dec-12-24 08:21AM - Scilex Holding Company Announces $17 Million Registered Direct Offering

Prior AI Reports for SCLX:
1. 2025-04-02 – Score: 46 – Target: 0.4500 – Highs: 0.3310 / 0.2996 / 0.28
high-insider-ownership-amidst-volatile-performance-and-financial-concerns

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-14T20:35:00Z - Denali Capital Acquisition Corp. Announces Shareholder Approval of Extension of Deadline to Complete Business Combination
B2 - 2025-04-11T13:00:00Z - Scilex Holding Company Announces 1-for-35 Reverse Stock Split
B3 - 2025-03-27T00:24:00Z - Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva
B4 - 2025-01-16T20:38:00Z - Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults
B5 - 2024-11-22T11:00:00Z - Scilex Holding Company Announces Receipt of Notice from Nasdaq
B6 - 2024-10-29T10:00:00Z - Scilex Holding Company, Following its Prior Announcement of the Record Date for a Dividend of Preferred Stock, Reiterates Information Previously Provided to Scilex Stockholders Regarding Manipulative and Naked Short Selling of Scilex Common Stock

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Scilex (SCLX).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

SCLX_OUT_3 [2025-04-29 06:43:24 -0400] 659 Bytes | 187 tokens | Cum: 2130 tkns (26.62% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**Scilex Holding Company Announces 1-for-35 Reverse Stock Split**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/04/11/3060090/0/en/Scilex-Holding-Company-Announces-1-for-35-Reverse-Stock-Split.htmlScilex Holding Company announced a 1-for-35 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SCLX_OUT_5 [2025-04-29 06:43:25 -0400] 963 Bytes | 291 tokens | Cum: 2423 tkns (30.29% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-23T16:14:10Z - BB's Stock Haven : Time for a strong rebound: Scilex Hol......
A2 - 2025-04-22T17:05:43Z - 12 Health Care Stocks Moving In Tuesday's Intraday Session - Akso Health (NASDAQ:AHG), Adagio Medica...
A3 - 2025-04-22T16:05:16Z - BB's Stock Haven : ALL TIME LOW SCLX : 4.0291 -0.6709 (......
A4 - 2025-04-22T13:23:47Z - Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Pref...
A5 - 2025-04-22T13:12:39Z - Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Pref...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

SCLX_OUT_7 [2025-04-29 06:43:25 -0400] 1181 Bytes | 448 tokens | Cum: 2873 tkns (35.91% of 8k)
==========================================================================

Showing A1 (chunk 1 of 8): A1:
**BB's Stock Haven : Time for a strong rebound: Scilex Hol...**Date: 2025-04-23Source: {'uri': 'investorshub.advfn.com', 'dataType': 'news', 'title': 'Investors Hub'}URL: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176103501Time for a strong rebound:

Scilex Holding Company (SCLX): 4.94 + 0.95 +(23.81%)

52w: 4.02 - 80.5

Less than 7 million shares.

https://dilutiontracker.com/app/search/SCLX

06/30/2024 5.18 million shares x 80.5 = 416 M

today: 6.95 million shares x 4.94 = 34 M

Apr 21, 2025 5.950

Apr 17, 2025 6.320

Apr 16, 2025 7.190

Apr 15, 2025 7.640

Apr 14, 2025 7.315

Apr 11, 2025 7.332

Apr 10, 2025 9.450

Apr 09, 2025 10.150

Apr 08, 2025 9.079

Apr 07, 2025 9.233

Apr 04, 2025 9.931

Apr 03, 2025 10.486

Apr 02, 2025 11.585

Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SCLX_OUT_9 [2025-04-29 06:43:26 -0400] 1183 Bytes | 304 tokens | Cum: 3179 tkns (39.74% of 8k)
==========================================================================

Showing A1 (chunk 2 of 8): for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 2025 to May 2, 2025

* Semnur is currently in discussions regarding strategic regional and/or worldwide collaborations and potential outright acquisition of SP-102. Any such transactions may have the potential to provide value in excess of $2.5 billion after the proposed business combination (the "Business Combination") with Denali Capital Acquisition Corp. (Nasdaq: DECA, the "SPAC").

* Based on an independent market research conducted by Syneos Health Consulting ("Syneos"), with the substantial intent in utilization for SP-102 (SEMDEXA™) with peak sales potential projected to reach $3.6 billion annually in the 5th year post launch of SP-102.

* Semnur Pharmaceuticals, Inc. ("Semnur"), a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX, "Scilex") annou

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SCLX_OUT_11 [2025-04-29 06:43:26 -0400] 1181 Bytes | 309 tokens | Cum: 3490 tkns (43.62% of 8k)
==========================================================================

Showing A1 (chunk 3 of 8): nced that it anticipates the filing of a Registration Statement on Form S-4 (the "Registration Statement") with the Securities and Exchange Commission (the "SEC")

* As previously disclosed, the Board of Directors of Scilex approved a resolution to authorize a potential dividend of up to 10% of Scilex's ownership interest in Semnur to Scilex shareholders, subject to registration statement of Semnur on file with the SEC. These shares will be freely tradable upon exchanging to Denali common shares after Business Combination.

SCILEX HOLDING COMPANY ANNOUNCES FDA HAS APPROVED OUR REQUEST FOR THE ORPHAN DRUG DESIGNATION FOR COLCHICINE FOR THE TREATMENT OF PERICARDITIS

(16-04) - Bron: Reuters

SCILEX HOLDING CO - RECEIVES HEALTH CANADA APPROVAL FOR ELYXYB FOR MIGRAINE TREATMENT

(15-04) - Bron: Reuters

SCILEX HOLDING CO - ROYALTYVEST GRANTED EXCLUSIVE RIGHTS TO LIDO PRODUCTS OUTSIDE U.S.

(

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SCLX_OUT_13 [2025-04-29 06:43:27 -0400] 1181 Bytes | 298 tokens | Cum: 3790 tkns (47.38% of 8k)
==========================================================================

Showing A1 (chunk 4 of 8): 27-02) - Bron: Reuters

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SCLX_OUT_15 [2025-04-29 06:43:27 -0400] 1181 Bytes | 305 tokens | Cum: 4097 tkns (51.21% of 8k)
==========================================================================

Showing A1 (chunk 5 of 8): completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia. It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; and Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA. Scilex Holding Company is headquartered in Palo Alto, C

Under the terms of the amendment, which was executed on April 16, 2025, the two companies have agreed to extend the deadline for completing the business combination to September 3

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SCLX_OUT_17 [2025-04-29 06:43:28 -0400] 1184 Bytes | 282 tokens | Cum: 4381 tkns (54.76% of 8k)
==========================================================================

Showing A1 (chunk 6 of 8): 0, 2025. This extension provides additional time for the companies to meet the merger conditions, including the possibility of a further extension to December 11, 2025, if mutually agreed upon. The timing of this merger is crucial, as InvestingPro analysis suggests the company is currently undervalued, with analyst price targets ranging from $218 to $490 per share, significantly above its current trading price of $4.76.

Scilex Holding Company has announced a change to the record date for its preferred stock dividend, moving it from April 11, 2025, to May 2, 2025. This adjustment is subject to further changes by the Board of Directors, with the payment date to be determined in the following 60 days. Scilex is focused on developing non-opioid treatments for pain management and has several commercial products, including ZTlido®, ELYXYB®, and Gloperba®, along with promising product candidat

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SCLX_OUT_19 [2025-04-29 06:43:29 -0400] 1183 Bytes | 258 tokens | Cum: 4641 tkns (58.01% of 8k)
==========================================================================

Showing A1 (chunk 7 of 8): es in various stages of development. The company emphasizes advancing patient outcomes in areas of acute and chronic pain, neurodegenerative, and cardiometabolic diseases.

Potential Positives

Scilex Holding Company has announced a new record date for its preferred stock dividend, indicating a commitment to returning value to its shareholders.

The company's focus on non-opioid pain management products positions it in a growing market with high unmet needs, potentially leading to significant revenue opportunities.

Scilex's FDA-approved products, such as ELYXYB® for migraines and ZTlido® for neuropathic pain, enhance its commercial portfolio, which may bolster future sales and investor confidence.

Fast Track designations from the FDA for product candidates like SP-102 and SP-103 demonstrate the company's potential for expedited development and market entry, which could lead to quicker

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SCLX_OUT_21 [2025-04-29 06:43:30 -0400] 302 Bytes | 86 tokens | Cum: 4729 tkns (59.11% of 8k)
==========================================================================

Showing A1 (chunk 8 of 8): revenue generation.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SCLX_OUT_23 [2025-04-29 06:43:31 -0400] 1135 Bytes | 313 tokens | Cum: 5044 tkns (63.05% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-22 8-K Item 7.01. Regulation FD Disclosure.

On April 22, 2025, Scilex Holding Company (the Company ) issued a press release announcing that its Board of Directors (the Board ) has approved a change to the previously announced record date of April 11, 2025 for its previously announced ...

S2 - 2025-04-21 8-K Item 1.01. Entry into a Material Definitive Agrmt.

As previously disclosed in the Curr Report on Form 8-K filed by Scilex Holding Company ( Scilex ) with the Securities and Exchange Commission (the SEC ) on September 3, 2024 (the Curr Report ), on August 30, 2024, Sem...

S3 - 2025-04-11 8-K Item7.01. Regulation FD Disclosure.

On April 11, 2025, Scilex Holding Company issued a press release with respect to a pending reverse split of its common stock. A copy of the press release is furnished herewith as Exhibit 99.1 to this Curr Report on Form 8-K (this Curr R...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

SCLX_OUT_25 [2025-04-29 06:43:32 -0400] 1181 Bytes | 289 tokens | Cum: 5335 tkns (66.69% of 8k)
==========================================================================

Showing S1 (chunk 1 of 4): S1:
Item 7.01. Regulation FD Disclosure.

On April 22, 2025, Scilex Holding Company (the Company ) issued a press release announcing that its Board of Directors (the Board ) has approved a change to the previously announced record date of April 11, 2025 for its previously announced dividend of Series 1 Mandatory Exchangeable Preferred Stock, par value $0.0001 per share, of the Company (the Dividend ) to its stockholders and certain other of its securityholders as of such record date (collectively, the Record Holders ). The new record date for the Dividend will be May 2, 2025 (the New Record Date ). Subject to the Boards right to change the New Record Date, the Dividend (unless otherwise determined by the Board) shall be paid on such date to be determined by subsequent resolutions of the Board, which payment date shall be within 60 days following the New Record Date (i.e., not later than

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SCLX_OUT_27 [2025-04-29 06:43:32 -0400] 1181 Bytes | 281 tokens | Cum: 5618 tkns (70.23% of 8k)
==========================================================================

Showing S1 (chunk 2 of 4): July 1, 2025) (such date as determined by the Board, the Payment Date ) and shall be apportioned on a pro rata basis among the Record Holders as previously announced by the Company.

The New Record Date may be changed by the Board for any reason at any time prior to the actual payment of the Dividend with any such change in the New Record Date to be disclosed by the Company in a Current Report on Form 8-K. Payment of the Dividend is conditioned upon the Board not having revoked the dividend prior to the Payment Date, including for a material change to the solvency or surplus analysis presented to the Board. A copy of the press release is attached as Exhibit 99.1 to this Current Report.

The information under this Item 7.01 of this Current Report is being furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of t

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SCLX_OUT_29 [2025-04-29 06:43:33 -0400] 1181 Bytes | 244 tokens | Cum: 5864 tkns (73.30% of 8k)
==========================================================================

Showing S1 (chunk 3 of 4): hat section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing. This report will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

The information in this Current Report may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements, other than statements of historical or current fact, are statements that could be deemed forward-looking statements, including, without limitation, statements relating to our declaration and payment of dividends. Forward-looking statements are based on the current beliefs, assumptions, and expectations of

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SCLX_OUT_31 [2025-04-29 06:43:33 -0400] 607 Bytes | 144 tokens | Cum: 6010 tkns (75.12% of 8k)
==========================================================================

Showing S1 (chunk 4 of 4): management and current market conditions. There can be no assurance that future dividends will be declared, and the payment of this Dividend is expressly conditioned on the Board not revoking the Dividend before the Payment Date, including for a material change to the solvency or surplus analysis presented to the Board....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

SCLX_OUT_33 [2025-04-29 06:43:40 -0400] 5885 Bytes | 1588 tokens | Cum: 7600 tkns (95.00% of 8k)
==========================================================================

This is our set of metrics for Scilex.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+-----------------------+
| Volume: 131,201 | Perf Month: -43.04% | Option/Short: No / Yes | Sales Y/Y TTM: 21.07% |
+--------------------+-----------------------+------------------------+-----------------------+
| Avg Volume: 65.43K | Perf Quarter: -69.25% | Short Float: 3.18% | ROE: - |
+--------------------+-----------------------+------------------------+-----------------------+
| Rel Volume: 2.02 | Index: - | Short Ratio: 2.53 | ROI: - |
+--------------------+-----------------------+------------------------+-----------------------+
| RSI (14): 33.01 | Market Cap: 34.37M | Short Interest: 0.17M | Sales Surprise: 7.84% |
+--------------------+-----------------------+------------------------+-----------------------+
| ATR (14): 1.21 | Shs Outstand: 183.24M | Beta: 1.13 | EPS Surprise: 31.15% |
+--------------------+-----------------------+------------------------+-----------------------+
| SMA20: -29.34% | Shs Float: 5.20M | Sales Q/Q: 10.68% | P/E: - |
+--------------------+-----------------------+------------------------+-----------------------+
| SMA50: -45.32% | Inst Own: 20.30% | Sales past 5Y: 16.35% | Earnings: Feb 26 |
+--------------------+-----------------------+------------------------+-----------------------+
| SMA200: -80.67% | Insider Own: 25.14% | Employees: 115 | |
+--------------------+-----------------------+------------------------+-----------------------+
| Perf Week: 5.32% | Insider Trans: 4.23% | Debt/Eq: - | |
+--------------------+-----------------------+------------------------+-----------------------+

The next section covers any insider trading by Scilex officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 55152000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -87747000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 4.95
Average Volume: 122964.62
30-Day High: 10.4125
30-Day Low: 3.99

[Detailed Financials: Q3 2024]
- Total Assets: $100,430,000.00
- Total Liabilities: $311,747,000.00
- Total Equity: $-211,317,000.00
- Current Assets: $39,855,000.00
- Current Liabilities: $281,537,000.00

[Income Statement: Q3 2024]
- Revenue: $14,436,000.00
- Net Income: $-4,388,000.00
- Gross Profit: $10,668,000.00
- Operating Income: $-19,917,000.00
- Earnings Per Share (EPS): -0.03

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-1,563,000.00

[Detailed Financials: Q2 2024]
- Total Assets: $104,544,000.00
- Total Liabilities: $319,236,000.00
- Total Equity: $-214,692,000.00
- Current Assets: $50,418,000.00
- Current Liabilities: $255,451,000.00

[Income Statement: Q2 2024]
- Revenue: $16,370,000.00
- Net Income: $-37,582,000.00
- Gross Profit: $11,980,000.00
- Operating Income: $-15,623,000.00
- Earnings Per Share (EPS): -0.31

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $6,881,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Scilex (SCLX).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Scilex.

2) MARKET_SCORE[]
This conversation was initiated because SCLX is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for SCLX.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, SCLX could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect SCLX to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Scilex.

11) ETHICAL_RATING[]
Rate Scilex’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Scilex.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

SCLX_IN_35 [2025-04-29 06:43:41 -0400] 126 Bytes | 29 tokens | Cum: 7830 tkns (97.88% of 8k)
==========================================================================

====================================
[2025-04-29 06:43:41] # Analysis Completed
Elapsed Time: 18.42 seconds